Iridex Corp (IRIX) is a publicly traded Healthcare sector company. As of May 20, 2026, IRIX trades at $1.07 with a market cap of $17.66M and a P/E ratio of 0.00. IRIX moved +3.45% today. Year to date, IRIX is -10.26%; over the trailing twelve months it is -1.87%. Its 52-week range spans $0.78 to $1.95. Analyst consensus is buy with an average price target of $2.75. Rallies surfaces IRIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Iridex Q1 Revenue $11.8M; Cyclo G6 Sales Up 14%: Iridex reported Q1 revenue of $11.8 million, down 1% year-over-year, as Cyclo G6 sales grew 14% to $3.6 million and retina revenue fell to $5.8 million; net loss narrowed to $0.5 million ($0.03/share) from $1.7 million. Cash at $4.6 million and guidance of $51 million–$53 million reaffirmed with positive cash flow.
| Metric | Value |
|---|---|
| Price | $1.07 |
| Market Cap | $17.66M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.95 |
| 52-Week Low | $0.78 |
| Volume | 127.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover IRIX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.75.